12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Company News  |  Deals

Asklepios, Baxter deal

Asklepios' Chatham Therapeutics LLC affiliate granted Baxter exclusive, worldwide rights to develop and commercialize Chatham's Biological Nano Particles adeno-associated virus vector therapy to treat hemophilia B....

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >